Casdin Capital, LLC
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Nov 2026 | $2,872,598,242 | Pooled investment vehicles (100%) |
| Apr 2025 to Mar 2026 | $2,942,598,662 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $2,643,698,992 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $2,705,553,673 | Pooled investment vehicles (100%) |
| Apr 2023 | $2,705,553,673 | Pooled investment vehicles (100%) |
| Apr 2022 to Mar 2023 | $5,202,118,702 | Pooled investment vehicles (100%) |
Schedule 13D/13G stakes
Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.
| Company | Schedule | Event date | Filed | Shares | % of class | Status |
|---|---|---|---|---|---|---|
| LAB Standard Biotools Inc. | 13D/A Merger opposition or support | Jun 6, 2026 | 5mo | 88,783,856 | 22.7% | Current |
| RLAY Relay Therapeutics, Inc. | 13G/A | Dec 31, 2025 | 9mo | 13,003,574 | 7.5% | Current |
| NGNE Neurogene Inc. | 13G/A | Dec 31, 2024 | 1y | 1,295,361 | 8.7% | Current |
A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 5 exited, below-5% or retired stakes
Portfolio style
Measured from the filed 13F common-share book for Sep 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-09-30, active share 97.8%; sector active share 90.5% against the combined 13F book's sector weights.
Over time 27 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+. Stocks and the top 10 weight count issuers: share classes of one company are one stock, and options are left out, so they can differ from the position count and top 10 concentration of GetInstitutionSummary and GetInstitutionPortfolio, which count each listed share class.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
48 common stock positions · as of Sep 30, 2026 · Δ vs Jun 30, 2026Portfolio Trend
Sector Breakdown
Common stock positions · as of Sep 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $2,295,707,115 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | +1,350,000 | 1,820,000 | $33,160,400 | |
| TSHA | Taysha Gene Therapies, Inc. | +650,000 | 3,900,000 | $18,993,000 | |
| GRAL | GRAIL, Inc. | +200,000 | 680,000 | $95,281,600 | |
| SRRK | Scholar Rock Holding Corp | +185,000 | 850,000 | $41,072,000 | |
| BEAM | Beam Therapeutics Inc. | +150,000 | 1,500,000 | $36,675,000 | |
| HIMS | Hims & Hers Health, Inc. | +100,000 | 800,000 | $23,832,000 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | +45,000 | 120,000 | $29,608,800 | |
| NGNE | Neurogene Inc. | +40,000 | 1,585,361 | $44,104,743 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | −795,000 | 1,250,000 | $25,837,500 | |
| PSNL | Personalis, Inc. | −250,000 | 2,300,000 | $37,444,000 | |
| — | −155,000 | 4,500,000 | $174,825,000 | ||
| GPCR | Structure Therapeutics Inc. | −145,000 | 1,030,000 | $32,208,100 | |
| GLUE | Monte Rosa Therapeutics, Inc. | −100,000 | 86,014 | $1,026,147 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TEM | Tempus AI, Inc. | 423,597 | $34,692,594 | |
| ORIC | Oric Pharmaceuticals, Inc. | 1,250,000 | $16,837,500 | |
| BIIB | Biogen Inc. | 50,000 | $11,294,000 | |
| EWTX | Edgewise Therapeutics, Inc. | 265,000 | $10,759,000 | |
| BNTX | BioNTech SE | 85,000 | $8,355,500 | |
| BRVE | Braveheart Bio, Inc. | 400,000 | $8,080,000 | |
| RAPP | Rapport Therapeutics, Inc. | 200,000 | $6,720,000 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Held | 2,577,333 | $529,023,371 | 23.04% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Held | 16,035,240 | $289,436,082 | 12.61% | |
| WGS |
GeneDx Holdings Corp.
Healthcare
|
Held | 3,707,164 | $268,027,957 | 11.68% | |
|
|
Reduced | 4,500,000 | $174,825,000 | 7.62% | ||
| ILMN |
Illumina, Inc.
Healthcare
|
Held | 530,000 | $145,050,400 | 6.32% | |
| GRAL |
GRAIL, Inc.
Healthcare
|
Added | 680,000 | $95,281,600 | 4.15% | |
| TXG |
10x Genomics, Inc.
Healthcare
|
Held | 1,050,000 | $94,878,000 | 4.13% | |
| LAB |
Standard Biotools Inc.
Healthcare
|
Held | 88,783,856 | $65,753,323 | 2.86% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Added | 1,585,361 | $44,104,743 | 1.92% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Added | 850,000 | $41,072,000 | 1.79% | |
| PSNL |
Personalis, Inc.
Healthcare
|
Reduced | 2,300,000 | $37,444,000 | 1.63% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
Added | 1,500,000 | $36,675,000 | 1.60% | |
| TEM |
Tempus AI, Inc.
Healthcare
|
NEW | 423,597 | $34,692,594 | 1.51% | |
| SRPT |
Sarepta Therapeutics, Inc.
Healthcare
|
Added | 1,820,000 | $33,160,400 | 1.44% | |
| GH |
Guardant Health, Inc.
Healthcare
|
Held | 185,000 | $32,996,600 | 1.44% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Reduced | 1,030,000 | $32,208,100 | 1.40% | |
| ALNY |
Alnylam Pharmaceuticals, Inc.
Healthcare
|
Added | 120,000 | $29,608,800 | 1.29% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Reduced | 1,250,000 | $25,837,500 | 1.13% | |
| HIMS |
Hims & Hers Health, Inc.
Healthcare
|
Added | 800,000 | $23,832,000 | 1.04% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 843,857 | $22,936,033 | 1.00% | |
| SEPN |
Septerna, Inc.
Healthcare
|
Held | 553,268 | $21,649,376 | 0.94% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
Held | 645,690 | $20,849,330 | 0.91% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
Held | 1,250,000 | $20,000,000 | 0.87% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Added | 3,900,000 | $18,993,000 | 0.83% | |
| AGMB |
AgomAb Therapeutics NV
Healthcare
|
Held | 1,550,000 | $17,205,000 | 0.75% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
NEW | 1,250,000 | $16,837,500 | 0.73% | |
| MRNA |
Moderna, Inc.
Healthcare
|
Held | 75,000 | $14,442,750 | 0.63% | |
| VCYT |
Veracyte, Inc.
Healthcare
|
Held | 276,308 | $12,721,220 | 0.55% | |
| DGX |
Quest Diagnostics Inc
Healthcare
|
Held | 50,000 | $11,653,500 | 0.51% | |
| BIIB |
Biogen Inc.
Healthcare
|
NEW | 50,000 | $11,294,000 | 0.49% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
NEW | 265,000 | $10,759,000 | 0.47% | |
| ABSI |
Absci Corp
Healthcare
|
Held | 973,260 | $10,482,010 | 0.46% | |
| PRME |
Prime Medicine, Inc.
Healthcare
|
Held | 3,167,175 | $9,675,719 | 0.42% | |
| BNTX |
BioNTech SE
Healthcare
|
NEW | 85,000 | $8,355,500 | 0.36% | |
| BRVE |
Braveheart Bio, Inc.
Healthcare
|
NEW | 400,000 | $8,080,000 | 0.35% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
NEW | 200,000 | $6,720,000 | 0.29% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Held | 355,000 | $4,281,300 | 0.19% | |
| QURE |
uniQure N.V.
Healthcare
|
Held | 150,000 | $3,624,000 | 0.16% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 1,228,190 | $2,100,204 | 0.09% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
Held | 148,333 | $1,990,628 | 0.09% | |
| PACB |
Pacific Biosciences Of California, Inc.
Healthcare
|
Held | 723,767 | $1,715,327 | 0.07% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Held | 282,312 | $1,157,479 | 0.05% | |
| EDIT |
Editas Medicine, Inc.
Healthcare
|
Held | 445,000 | $1,143,650 | 0.05% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Reduced | 86,014 | $1,026,147 | 0.04% | |
| KARD |
Kardigan, Inc.
Healthcare
|
Held | 50,000 | $737,500 | 0.03% | |
| RXRX |
Recursion Pharmaceuticals, Inc.
Healthcare
|
Held | 165,323 | $682,783 | 0.03% | |
| DNA |
Ginkgo Bioworks Holdings, Inc.
Healthcare
|
Held | 36,493 | $468,205 | 0.02% | |
| TNYA |
Tenaya Therapeutics, Inc.
Healthcare
|
Held | 361,969 | $218,484 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.